New Deadlines for Stakeholder Feedback

CADTH recently experienced problems with its website hosting platform that prevented users from downloading documents from – including draft reimbursement recommendations and stakeholder feedback forms.

The issue has been resolved and all documents on our website are now accessible to everyone.

When the problem was identified, CADTH contacted sponsors and patient groups and provided them with copies of the draft recommendations and feedback forms for the reimbursement reviews currently open for feedback. Sponsors also received the reconsideration forms.

Today, we are extending our stakeholder feedback deadlines as follows:

Drug Therapeutic Area Revised Timelines for Stakeholder Feedback
Non-Oncology Drugs
lemborexant (Dayvigo) Insomnia



September 2, 2022: Deadline for sponsors to provide feedback or submit a request for reconsideration.

September 6, 2022: Deadline for patient groups and clinician groups to provide feedback on the draft recommendations.

berotralstat (Orladeyo) Hereditary angioedema
semaglutide (Wegovy) Weight management
 ruxolitinib (Jakavi) Graft versus host disease

Eligible stakeholders who were not contacted by CADTH can now access the draft recommendations and feedback forms on 

We apologize for any inconvenience and thank you for your patience.